5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Asthma and COPD Drugs Market is segmented by Drug Class, Indication, and Geography.
Fastest Growing Market:
Asthma and COPD drugs market is expected to witness a CAGR of 4.2% during the forecast period. Certain factors that are driving the market growth include an increase in incidence and prevalence of asthma and COPD, technological advancements, and growing geriatric population.
Asthma is a chronic respiratory disease, which blocks the airways of the lung because of mucus production, inflammation, and tightening of muscles. Similarly, chronic obstructive pulmonary disease (COPD) is caused by the blockage in the airways, further resulting in difficulty in breathing. Asthma and COPD drugs are drugs that are used to treat these aforementioned respiratory diseases.
|By Drug Class|
|Chronic Obstructive Pulmonary Disease|
Report scope can be customized per your requirements. Click here.
According to the American Academy of Allergy Asthma and Immunology (AAAI), in 2016, approximately 8.3% of children in the United States were found to have asthma. Boys were to some extent more likely to have asthma than girls at a rate of 9.2% and 7.4%, respectively. Asthma incidence among children increased from 8.7% in 2001 to 9.4% in 2010 and then declined to 8.3% in 2016. Although not all changes were statistically noteworthy, a similar outline was observed among the sub-demographic groups, except the Mexican/Mexican-American children, among whom asthma prevalence increased from 5.1% in 2001 to 6.5% in 2016. The substantial increase in prevalence and incidence of asthma has led to an increase in the patient population, which has, in turn, increased the demand for these drugs.
Moreover, the rise in the number of initiatives undertaken by government and nongovernment organizations is increasing the overall revenue. For instance, CDC’s National Asthma Control Program (NACP) provides funds for educating asthma affected patients. Such initiatives are likely to increase awareness about asthma, which will increase the adoption of drugs in the treatment of asthma, leading to verticle growth.
To understand key trends, Download Sample Report
North America is expected to dominate asthma and COPD drugs market during the forecast period. This growth can be attributed to the rising incidence of diseases such as COPD and asthma. According to the Annals of the American Thoracic Society, asthma costs the U.S. economy more than USD 80 billion annually in medical expenses, missed work and school days and deaths. The rise in the number of patients affected by these diseases, increases the demand for these drugs for the treatment of target disease, thereby boosting growth of this region.
In addition, the local presence of key pharmaceutical players, advanced healthcare infrastructure, aging population, high disposable income, and lifestyle changes are factors contributing to the overall growth of the North America asthma and COPD drugs market.
To understand geography trends, Download Sample Report.
The industry is competitive in nature with key players involved in mergers & acquisitions, new product development, collaborations & partnerships, and expansion strategies to augment market penetration. Few major players. Companies, like Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Grifols, Novartis AG, Pfizer, Roche Holding AG, and Teva Pharmaceutical, among others, hold the substantial market share in the asthma and COPD drugs market.
For instance, in May 2017, Koninklijke Philips N.V. entered into a definitive agreement to acquire Respiratory Technologies, Inc. (RespirTech) with an aim to expand its respiratory care product portfolio.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Incidence and Prevalence of Asthma and COPD
4.2.2 Technological Advancements
4.2.3 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Stringent Government Regulations for the Product Approval
4.3.2 Side Effects Associated with Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Drug Class
18.104.22.168 Short Acting Beta-2 Agonists
22.214.171.124 Long Acting Beta-2 Agonists
126.96.36.199 Anti-cholinergic Agents
5.1.2 Anti-inflammatory Drugs
188.8.131.52 Oral and Inhaled Corticosteroids
184.108.40.206 Phosphodiesterase Type-4 Inhibitors
220.127.116.11 Other Anti-inflammatory Drugs
5.1.3 Monoclonal Antibodies
5.1.4 Combination Drugs
5.2 By Indication
5.2.2 Chronic Obstructive Pulmonary Disease
5.3.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.3.4 Middle East & Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East & Africa
5.3.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.2 Boehringer Ingelheim
6.1.5 Merck & Co.
6.1.7 Roche Holding AG
6.1.8 Sumitomo Dainippon Pharma
6.1.9 Teva Pharmaceutical
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments